Lymphoma, Large B-Cell, Diffuse
108
5
11
46
Key Insights
Highlights
Success Rate
75% trial completion
Published Results
26 trials with published results (24%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
13.9%
15 terminated out of 108 trials
75.4%
-11.1% vs benchmark
12%
13 trials in Phase 3/4
57%
26 of 46 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 46 completed trials
Clinical Trials (108)
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
A Study of LY4152199 in Participants With Previously Treated B-cell Cancers (BAF_FRontier-1 )
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell
A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers
EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection
Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol
LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)
A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)
A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies
Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study
CD70-targeted immunoPET Imaging of Malignant Cancers
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL